New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
06:11 EDTIMUCImmunoCellular anticipates strategies and milestones for ICT-107
ImmunoCellular Therapeutics provided an update on the Company's anticipated 2014 corporate strategies and milestones. Company said "As we enter 2014, we are focused on advancing our pipeline of cancer vaccines, and on creating and delivering value to all our stakeholders. We are committed to making the best data-driven decisions we can about how we move forward and invest our resources. We are confident that our clinical programs have meaningful therapeutic and commercial potential, and intend to ensure that our strategies are driven by appropriate medical and scientific rationales. We are also confident that we have more than enough resources to achieve our near-term goals and that we will continue our progress in building a leading cancer immunotherapy company and transforming the treatment of cancer." The next steps for ICT-107 include: continue to monitor overall survival for patients in the phase II trial; analyze immunological data relating to the patients and the vaccine, to inform the phase III design and potential patient selection; antigen expression in patient tumor samples, to determine if there is a correlation between the expression of certain antigens in patients' tumors and OS and PFS; dendritic cell characterization data, focusing on two indicators of dendritic cell activation that are statistically predictive of OS in the treated patients; analysis of patient samples for vaccine-induced T-cell activation, to enable determination of a potential relationship between vaccine responders and OS.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 19, 2015
09:20 EDTIMUCOn The Fly: Pre-market Movers
Subscribe for More Information
06:12 EDTIMUCImmunoCellular signs manufacturing agreement with Pharmacell B.V.
ImmunoCellular established an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma. This agreement with PharmaCell, a European contract manufacturing organization, focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use